CanSino Biologics Inc's (CanSinoBIO) single-dose Covid-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed.

Researchers decided to lower the dosage after a few participants developed fever and headaches graded at Level 2 severity - the second-lowest of four levels...